DDInter1397 DDInter621
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy.
Paroxetine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Paroxetine {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Felodipine
Felodipine {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Paroxetine {u} (Compound) causes {v} (Side Effect) Angina pectoris
Angina pectoris {u} (Side Effect) is caused by {v} (Compound) Dasatinib
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Paroxetine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Paroxetine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Paroxetine {u} (Compound) palliates {v} (Disease) bipolar disorder
bipolar disorder {u} (Disease) is palliated by {v} (Compound) Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Paroxetine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Amiodarone
Amiodarone {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Paroxetine {u} (Compound) downregulates {v} (Gene) CDCA4
CDCA4 {u} (Gene) is downregulated by {v} (Compound) Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Paroxetine {u} (Compound) downregulates {v} (Gene) CDCA4
CDCA4 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Paroxetine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Levomilnacipran (Compound) and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Paroxetine (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Levomilnacipran (Compound) and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Paroxetine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Felodipine (Compound) and Felodipine may lead to a major life threatening interaction when taken with Edoxaban
Paroxetine (Compound) causes Angina pectoris (Side Effect) and Angina pectoris (Side Effect) is caused by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Edoxaban
Paroxetine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Paroxetine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Paroxetine (Compound) palliates bipolar disorder (Disease) and bipolar disorder (Disease) is palliated by Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Paroxetine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Amiodarone (Compound) and Amiodarone may lead to a major life threatening interaction when taken with Edoxaban
Paroxetine (Compound) downregulates CDCA4 (Gene) and CDCA4 (Gene) is downregulated by Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Paroxetine (Compound) downregulates CDCA4 (Gene) and CDCA4 (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Edoxaban